![]() No currently available human DNA vaccines.Image: DNA to mRNA to Antigen (protein) within a cell Image: DNA Plasmid with gene for SARS-CoV2 antigen There is no risk of infection but there is a possibility that the immune system does not fight against the antigen (tolerance to the antigen). These vaccines use DNA plasmids containing a gene for SARSCoV-2 along with additional genetic elements that will produce some of the same antigenic proteins as the disease-causing virus. Improved efficacy and safety but require high doses to confer immunity. These vaccines are similar to replicating viral vector vaccines except that they cannot replicate inside the body as the key viral replication genes is deleted from the low pathogenic vector virus. Image: The virus replicates inside the body ![]() Image: Viral vector encoding target antigen Image: Disease-causing virus + Low – pathogenic virus This creates a strong immune response but may not work for people who are already immune to the low pathogenic virus. These vaccines use low-pathogenic viruses, which are largely harmless, and alter them into viral vectors that will produce some of the same proteins as the disease-causing virus. Require booster doses as the immunity conferred by these vaccines is weaker than live vaccines. They are safer as the virus is already dead. These vaccines contain whole virus particles, that have been killed or inactivated to keep Take antigens from the infecting viruses and present them to immune cells.Some attenuated vaccines might not be suitable for people with compromised immune systems. These vaccines contain live virus particles that have been weakened to keep them from causing disease. US Food and Drug Administration COVID-19 Vaccines. Addressing the Cold Reality of mRNA Vaccine Stability. Challenges in ensuring global access to COVID-19 vaccines: Production, affordability, allocation, and deployment. Wouters O.J., Shadlen K.C., Salcher-Konrad M., Pollard A.J., Larson H.J., Teerawattananon Y., Jit M. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. The COVID-19 Pandemic: Effects on Low- and Middle-Income Countries. Regional and international cooperation can also play a big role in ensuring equity in vaccine access and vaccination.ĬOVAX developing countries hesitancy vaccine equity.īong C.L., Brasher C., Chikumba E., McDougall R., Mellin-Olsen J., Enright A. However, existing strengths of local and regional communities can be leveraged to provide innovative solutions and mitigate some of the challenges. Lastly, attention will need to be paid to ensuring adequate uptake of vaccines since vaccine hesitancy has already been reported for COVID vaccines. Several vaccines also require ultra-cold temperatures for storage and transport and therefore the need for specialized equipment and reliable power supply which may also not be readily available. This would require logistical and trained personnel support that can be hard to come by for resource-poor nations. Once supplies are made available, vaccines will have to be distributed and administered to entire populations-with considerations for individual risk level, remote geography, cultural and socio-economic factors. ![]() Inequities in vaccine supply are already evident with resource-rich nations having secured a large chunk of the available vaccine doses for 2021. Developing nations, however, face monumental challenges in procurement, allocation, distribution and uptake of vaccines. Mass vaccination of the global population offers hope to curb the spread. Vaccines offer a hope toward ending the global pandemic caused by SARS-CoV2.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |